Brought to you by 
Allergen Research raises $17mm through Series A; advances peanut allergy immunotherapy
21 Apr 2021
Executive Summary
Allergen Research Corp. (developing therapies to protect children with food allergies from accidental exposure) raised $17mm through its Series A round. Longitude Capital led the round, and joins Allergen’s board. The non-profit awareness group Food Allergy Research & Education (FARE), which helped found the company in 2011, also contributed.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Allergen Research raises $17mm through Series A; advances peanut allergy immunotherapy
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice